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Abstract
Chronic rhinosinusitis (CRS) is a chronic inflammation of the mucosa of the nose and paranasal sinuses affecting
approximately 11% of the adult population in Europe. Inadequate immune responses, as well as a dysbiosis of the
sinonasal microbiota, have been put forward as aetiological factors of the disease. However, despite the prevalence
of this disease, there is no consensus on the aetiology and mechanisms of pathogenesis of CRS. Further research
requires in vitro models mimicking the healthy and diseased host environment along with the sinonasal microbiota.
This review aims to provide an overview of CRS model systems and proposes in vitro modelling strategies to
conduct mechanistic research in an ecological framework on the sinonasal microbiota and its interactions with the
host in health and CRS.
Background
The upper respiratory tract is one of the primary body
sites of contact with the outside environment and its
physical, chemical and infectious agents. It is therefore
unsurprising that upper respiratory tract infections are a
major health concern. Chronic rhinosinusitis (CRS) is a
disease that affects 10.9% of the adult population in Eur-
ope [1]. It is defined as chronic inflammation (> 12 weeks)
of the nasal and paranasal sinus mucosa, characterised by
two or more symptoms, one of which should be either
nasal obstruction, congestion or nasal discharge and is
further identified by facial pain, pressure and/or reduction
or loss of smell [2]. Supportive objective evidence includes
rhinoscopic or endoscopic findings of polyps and/or puru-
lent discharge and/or oedema or mucosal obstruction in
the middle meatus and/or ethmoid region. Next to this, a
CT scan can demonstrate mucosal changes within the
paranasal sinuses [3]. CRS patients are typically classified
in two major clinical subgroups or phenotypes based on
the presence or absence of nasal polyps (NP) (respectively
CRSwNP and CRSsNP) [2, 3], although endotypes and
clusters can be distinguished within these subgroups,
based on inflammatory profiles [3, 4]. Despite the high
prevalence of CRS, there is no consensus about the aetiology
of the disease [5]. In recent years, however, understanding of
the importance of the sinonasal microbiome in this disease
is emerging [6–10]. The view that a respiratory microbiota
in equilibrium contributes to host health by immune prim-
ing and provision of colonisation resistance, similar to the
gut microbiome, gains interest [11–14]. Analogously, a dis-
rupted airway microbiota could decrease resistance to
pathogen infection and overgrowth and result in inflamma-
tory responses [10, 15, 16]. Culture-independent techniques,
such as next-generation sequencing, have enabled in-depth
study of the differences in community structure in healthy
and CRS upper respiratory tracts [7, 17–25].
In addition to in vivo human research, mouse, rabbit
and sheep models to further study CRS have been devel-
oped, despite the ambiguous aetiology of the disease (as
reviewed in Shin [26]). Current animal models are either
based on infection with specific bacterial or fungal path-
ogens [11, 27] or on immunostimulation causing allergic
rhinosinusitis [28, 29]. In vivo animal models of CRS
can be used to study more complex immune responses,
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pathogen invasion in a natural microbiota context, and
histologic and systemic effects [11, 29, 30] than in vitro
models. Differences in sinus morphology, disease devel-
opment, microbiome, pathogens and immune response
between humans and test animals should be taken into
account in the interpretation of results [26]. Although in
vivo observations and intervention studies supply valu-
able information, there is a need for in vitro models ac-
cording to the 3R principle (refinement, reduction,
replacement). Adequate in vitro models mimicking the
in vivo environment allow initial testing of numerous
conditions such as effects of pathogen or allergen expos-
ure on the host, influence of physical changes in the host
microenvironment on both host and microbiota or
exploration of the potency of probiotics or biologicals in
disease prevention and/or control. Subsequently, the
most promising settings can be selected for animal stud-
ies, hereby refining the in vivo research and reducing the
required number of laboratory animals [31]. To study
host-microbe interactions in health and disease, systems
mimicking the host mucosal environment and its complex
microbiota in a reproducible manner have recently been
developed, i.e. in our research group, for the human gastro-
intestinal tract [32–34] and the oral cavity [35]. In order to
study airway diseases and mechanistically understand host-
microbe interactions, the development of similar, represen-
tative models for the respiratory tract is essential.
In this review, a short overview of the main character-
istics of the sinonasal CRS environment is given (the
reader is referred to Hamilos [36], Hamilos [37], Scheck-
enbach and Wagenmann [38] and Stevens et al. [39] for
reviews on the immune response in CRS and to Mahda-
vinia et al. [40] and Hoggard et al. [41] for the micro-
biota in CRS). Furthermore, we aim to review the
current methods to study airway host-microbe interac-
tions in vitro and propose in vitro modelling strategies
to conduct mechanistic research in an ecological frame-
work on the sinonasal microbiota and its interactions
with the host in health and CRS.
The sinonasal microenvironment
Epithelial lining of the sinonasal cavities
The nose and paranasal sinuses (the maxillary sinuses,
the ethmoid sinuses, the sphenoid sinuses and the
frontal sinuses) form a specific niche within the human
body. They consist of a unified system of skin and mu-
cosal surfaces and form the primary site of contact with
inhaled air in the respiratory tract. The nostrils and an-
terior nares are lined with keratinized stratified squa-
mous epithelium and contain serous and sebaceous
glands [42]. The surfaces of the nasal cavity and the
paranasal sinuses on the other hand are carpeted with
typical respiratory epithelium with pseudostratified cili-
ated columnar epithelium and are characterised by the
presence of basal cells and mucin-secreting goblet cells [43].
The activity of the goblet cells results in the presence of a
mucus layer, which is continuously removed by mucociliary
clearance and subsequently collected in the nasal cavity.
CRS-associated sinonasal microenvironment
The inflammatory state of the sinonasal epithelium of
CRS patients renders their sinonasal cavities different
from those in healthy individuals. Inflammatory tissue is
often characterised by hypoxia, a low level of oxygen in
tissues, typically occurring when available oxygen levels
are between 0.5 and 3% [44], and altered interleukin (IL)
secretion (e.g. IL-13), both factors inducing goblet cell
hyperplasia [45, 46], mucus hypersecretion [46–48] and
increased mucin expression [45–47]. These factors result
in increased thickness of the mucus layer and mucosta-
sis, a lack of mucus flow resulting in mucus accumula-
tion. Furthermore, the diameters of the ostia, the
openings connecting the sinus cavities with the nasal
cavity, can be severely reduced or completely obstructed.
Leung et al. [49] found uni- or bilateral osteomeatal
complex obstruction in 64.4% of CRSsNP patients (n =
144) and in 75.0% in CRSwNP patients (n = 123), from a
patient population requiring surgery for CRS. This
causes a reduction in sinus aeration (hypoxia) and an
additional accumulation of mucus and other sinus secre-
tions. Hypoxia itself induces tissue remodelling (e.g.
polyposis) and upregulation of inflammatory pathways
[44, 50]. Hypoxia can decrease the expression of anti-
microbial proteins [51], facilitate the growth of anaerobic
bacteria [52] and eventually result in increased inflam-
matory tissue damage [53].
An improper epithelial barrier function, with increased
paracellular permeability and decreased tight junction
expression, has also been linked to the CRS disease
phenotype [54–56]. Possibly due to the impaired barrier
function of damaged epithelium, CRS patients have sig-
nificantly increased nasal airway surface liquid (ASL)
glucose concentrations compared to control patients
[57]. In contrast, carbon sources, such as glucose, are ac-
tively depleted from ASL by healthy airway epithelium
[58]. The increased glucose concentration in CRS ASL
might facilitate bacterial growth by increased carbon
source availability and reduced antimicrobial protein se-
cretion via a bitter taste receptor (type 2 receptor)-medi-
ated pathway [57]. Bitter taste receptors have recently
been identified as players in innate sinonasal immunity
against bacterial invasion and biofilm formation through
nitric oxide production, and increased ciliary beating
upon activation by bacterial quorum sensing molecules
and their (dys)function could play a role in CRS recalci-
trance [59–62].
The production of antimicrobial proteins (AMP), such
as lysozyme, lactoferrin, PLUNC (palate, lung, and nasal
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epithelial clone) proteins and defensins, and the secretion
of immunoglobulin A (IgA) are protective mechanisms in
the upper respiratory tract (URT) [63]. Altered profiles of
these compounds have been associated with CRS patho-
genesis. Decreased short PLUNC-1 (SPLUNC-1) has been
observed in CRSwNP [64] and CRSwNP polyp tissue,
compared to control tissues [65]. Decreased SPLUNC-1
also appeared to be associated with positive Pseudomonas
aeruginosa bacterial colonisation and poor clinical out-
comes [64, 66]. It has been demonstrated in nasal polyp
cultures at air-liquid interface (ALI) that IL-13 has a
downregulating effect on SPLUNC-1 expression [67].
Next to AMP, the epithelium has the ability to produce a
broad array of cytokines and chemokines to modulate im-
mune responses towards both commensal and invading
microorganisms. Various studies have yet shown altered
cytokine profiles in cell cultures from CRS patients com-
pared to non-CRS controls [54, 68, 69]. Distinctive cyto-
kine profiles are observed between CRSwNP and CRSsNP
[2] and the different endotypes therein [3, 4]. CRSsNP ap-
pears to display a TH1-skewed cytokine profile, while
CRSwNP is more commonly characterised by a TH2 re-
sponse and eosinophilic NP in Caucasian patients [70, 71].
In contrast, an interferon-γ (IFN-γ)- and/or IL-17-biased
profile with neutrophilic NP appears more typical in Asian
CRSwNP patient populations [72]. An overview of the
most outstanding parameters of the CRS mucosal envir-
onment is presented in Fig. 1.
Bacterial microbiome of the sinonasal cavities
Composition of the sinonasal bacterial communities
In recent years, interest in the sinonasal cavity micro-
biome has increased, and the use of molecular methods
to study microbial communities has enabled character-
isation of the sinonasal microbiota, bypassing cultivation
bias [7, 17–25]. They show that the sinonasal microbiota
is very diverse and highly variable between individuals
[7, 17–25] and indicate a high temporal variability within
individuals [17].
The microbiome of the sinonasal cavities appears to
be characterised by the high relative abundance of three
phyla: Firmicutes, Actinobacteria and Proteobacteria
[17–19, 25]. Corynebacterium and Propionibacterium
species have been found at high abundances in most
individuals [17, 18, 24, 25, 73]. The species richness in
the nasopharynx of healthy westernised adults varied
greatly between subjects and time points and has been
estimated (Chao1 index) to be between 6 and 110 (aver-
age = 50, n = 97) [17]. Yan et al. [25] reported estimated
species richness (Chao1 index) in the anterior naris,
Fig. 1 Schematic representation of CRS tissue. A proposed model for the changes of the sinonasal environment during CRS. Increased mucus
production and/or goblet cell hyperplasia can result in a mucus layer with increased thickness (I). Changes in sinus microbiota can be observed,
more specifically the abundances of CRS-associated pathogens S. aureus, P. aeruginosa, S. pneumoniae and H. influenza. Proposed changes involve
decreased epithelial integrity (III: defective epithelial barrier function), with increased glucose concentrations in the airway surface liquid (II),
decreased recognition of acyl-homoserine lactones by T2R38 receptors, altered cytokine production and decreased antimicrobial protein and
immunoglobulin production that occur in CRS compared to healthy tissue. These changes potentially provide an environment that promotes
pathogenic bacterial growth and invasion of the epithelial barrier (IV), resulting in chronic inflammation. S. aureus has the ability to produce a
super-antigen, which evades conventional immune response and directly elicits eosinophilia and a TH2-skewed immune response (IL-5, IL-13,
IL-4), whereas IFN-γ induces a TH1-skewed immune response (figure adapted from Mahdavinia et al. [40])
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middle meatus and sphenoethmoidal recess between 200
and 400 (n = 179). Healthy sinonasal cavities are rela-
tively nutrient-poor niches in the human body for mi-
crobial colonisation [74]. As a result, the bacterial
density in the sinonasal cavities is estimated to be at
least 10 times lower in comparison to the oral cavity
(based on 16S copy numbers in sample) [75].
Dysbiosis in CRS
Dysbiosis of the bacterial community composition, a dis-
ruption of the equilibrium and mutualistic relationships
between commensal microorganisms mutually and with
the host epithelium, has been implied in the aetiology,
pathogenesis and recalcitrance of CRS [9–11, 13, 41].
Mackenzie et al. [10] suggested that the bacterial com-
munity associated with CRS is dysbiotic and that the
ecological networks in these communities are fragmen-
ted. They proposed Burkholderia and Propionibacterium
as keystone genera in healthy ecological networks [10].
It remains however unclear whether an imbalance in the
local microbiota and/or colonisation by pathogenic spe-
cies elicits an immune response and results in a chronic
inflammatory condition or whether an initial inflamma-
tion of the epithelium and/or sinus obstruction provides
a platform for sustained bacterial dysbiosis, resulting in
a CRS phenotype [6, 37, 63]. In addition, the interplay
between the (inadequate) host immune response and the
microbiota (in a state of dysbiosis) might also be ex-
planatory for the CRS phenotype [76]. Apart from the
causality of dysbiosis for CRS, the sinonasal microbiome
could play a role in the self-perpetuation of the disease
and be decisive in the therapeutic outcome. Several
studies have suggested that the diseased CRS sinonasal
environment is characterised by a higher bacterial load
and/or a lower diversity. However, contradictory results
have been observed. Several research groups [11, 20, 72,
77] detected no difference in bacterial load between CRS
and non-CRS patients, although a reduced diversity was
observed in CRS patients. Contrarily, a higher bacterial
load [7, 73] and increased diversity [6] were observed in
other studies comparing (refractory) CRS patients to
non-CRS controls. Aurora et al. [6] analysed nasal lavage
fluid of CRSwNP, CRSsNP and control patients, which,
contradictorily to the observations of Aurora et al. [6],
revealed a lower species diversity and an increased bac-
terial burden in CRS patients compared to controls. By
comparing the bacterial load in CRS and non-CRS
patients, it has been proposed that the bacterial load in
the sinonasal cavity is defined, but that the community
composition is rather influenced by conditions such as
illness and antibiotic use [11, 72, 78]. The lack of con-
sensus on a specific bacterial profile associated with CRS
could be a result of the diversity of DNA collection
method and the sampling place within the sinonasal
environment. Furthermore, a history of antibiotic use in
CRS, the phenotype and severity of the disease, and dis-
ease subgroups can be confounding factors. Typically,
only small patient and control cohorts (e.g. respectively
9 and 6, [20]) can be used for sinus microbiota sampling
due to the requirements to stay off antibiotics for
4 weeks prior to surgery and the difficulty of sampling
via endoscopic sinus surgery [20]. The most important
confounding factors are antibiotic and corticosteroid use
in case of CRS, as these are known to severely impact
microbiota diversity [22, 79]. Biswas et al. [20] selected
CRS patients that were off antibiotics for 4 weeks prior
to surgery. The impact of this selection criterion is how-
ever unclear, as Feazel et al. [22] reported a significant
reduction in species richness and evenness as a result of
antibiotic use 12 weeks prior to sampling. The CRS
patients sampled by Abreu et al. [11] all had a history of
antibiotic use.
Biofilm formation in CRS
Next to their community composition, the physiological
state in which bacteria are present on the mucosal sur-
face has importance in the CRS context. Biofilm forma-
tion is a commonly observed survival strategy among
microorganisms in which a microbial community is
enclosed in an exopolymer matrix of their own making
and attached to a surface. Biofilms can have a complex
structural organisation, which enables intense interactions
between the composing organisms. They provide protec-
tion from physicochemical environmental stressors such
as shear stress and harmful compounds. Especially
relevant in a healthcare context is the enhanced antibiotic
resistance observed in biofilms, which can be a factor of
1000 higher than the same species in planktonic form [80,
81]. Chronic disease, extreme resistance to antibiotic
treatment and repeated acute exacerbations are character-
istic of biofilm-mediated diseases and are also observed in
CRS patients [70, 82].
Biofilm formation in CRS can be confirmed by elec-
tron or laser microscopy on tissue biopsies [73, 83] and
has been associated with more severe disease and worse
treatment outcome after endoscopic sinus surgery in
comparison with non-biofilm CRS [84, 85].
Modelling the URT microenvironment and
microbiota
Representative in vitro models of the upper respiratory
tract and its microbiota can provide an elegant platform
to conduct mechanistic research on chronic rhinosinusi-
tis. A proper in vitro model allows the exploration of a
number of fundamental hypotheses in a simplified and
controlled environment and selection of the conditions
subsequently to be tested in vivo. Due to the ambiguous
aetiology of CRS, an optimal model should comprise, in
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close interaction, host components as well as microbial
components. An overview of these techniques is
presented in Fig. 2.
Requirement host interface A first constituent of the
host in vitro microenvironment is the respiratory epithe-
lium lining the deeper sinonasal cavity. It forms the pri-
mary site of interaction with the external environment
and its microbiota. Incoming microbes have to cope
with the innate (and adaptive) immune defences during
attachment and growth. Therefore, in vitro models
should include a differentiated epithelial structure with
ciliated and non-ciliated, goblet and basal cells, with the
following functionalities: mucus production, ciliary
movement, barrier function and cytokine, chemokine
and AMP secretion. Furthermore, apical-basolateral
differentiation is needed for bacterial attachment.
Currently, the only in vitro models expressing these
traits are differentiated ALI epithelial cell cultures and
organotypic explants [86].
Another point of attention is the altered physical host
conditions in a CRS environment. Mechanistic research
to address the question whether inflammation versus in-
fection causes CRS requires a model in which a diseased
host environment can be induced to observe the effects
of inflammation or defective immune defence to the
resident microbiota. A functional immune component is
a second requirement of a sinonasal host-microbe inter-
action (HMI) model. This condition could be met by the
incorporation of immune cells [87]. Ideally, the TH2- or
TH1/TH17-skewed immune responses in the CRS sub-
and endotypes, as previously described [3, 4], should be
comprised in the model.
Requirement microbial interface Research on hypoth-
eses regarding the role of microorganisms in CRS aeti-
ology and pathogenesis on the other hand requires a
healthy host component reacting to an infecting patho-
gen or microbiota in dysbiosis. The microbial compart-
ment of a CRS model should consist of a diverse,
complex community, as observed in vivo. To sustain a
representative in vitro sinonasal microbiome, a host
compartment providing the correct microenvironment
as well as a representative healthy or CRS inoculum is
Fig. 2 Schematic overview of the categories of cell culture used to model airway tissue and host-microbe interaction in the airways. Black arrows indicate
where addition of bacteria, bacterial cell wall compounds and/or other antigens is possible to mimic host-microbe interaction. a Two-dimensional (2D)
submerged culture, also known as conventional monolayers. Cells are typically cultured directly on a substrate such as plastic. b Suspension culture of
non-adherent cells, e.g. undifferentiated immune cells. c Two and one-half-dimensional (2.5D) culture. Cells are cultured on top of a layer of ECM. d 2D
culture at air-liquid interface (ALI). During ALI conditions, cells cultured on porous (membrane) inserts are deprived of medium in the apical compartment,
exposing them to the atmosphere and requiring them to take up nutrients from the basolateral compartment. e Differentiated ALI culture. Histologically
realistic epithelial tissues can be constructed in stages, with initial assembly of airway epithelial cells into an epithelial cell layer (2D monolayer) on a
submerged culture insert, followed by exposure of these cells to an air-liquid interface during a period of 2–4 weeks to induce the formation of polarised,
pseudostratified airway epithelium with basal cells, ciliated cells and mucin-secreting goblet cells. f Cell culture in microfluidic model. ALI culture in a
microfluidic model is an approach that mimics the in vivo environment more closely than static cell culture models. g 3D scaffold culture. Cells are
cultured in and/or on biomimetic scaffolds, submerged or at ALI. h Nasal or sinus tissue explants. Excised nose or sinus epithelium from patients or
healthy controls is cultured on a tissue culture insert that is either submerged in medium or maintained at an air-liquid interface. i Multicellular models.
The combination of different cell types within a model is a strategy to more accurately represent the host microenvironment and the interactions therein.
Airway epithelial cells can be combined with endothelial or immune cells to mimic host-microbe interaction on different levels
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needed. As elaborated above, it is still not clear whether
a CRS microbiota composition, distinctive from a
healthy sinonasal microbiota, exists; therefore, it might
be of more interest to investigate the functional differ-
ences between healthy and CRS communities.
In vitro CRS models are still at an early developmental
phase. Existing models are limited to either host-only
models, represented by ex vivo tissues, primary cell cul-
tures and immortal cell lines, or microbe-only models.
Microbial models for CRS lack the diverse community
composition seen in the sinonasal environment but are
rather focused on limited species competition or inter-
action assays (e.g. between Staphylococcus aureus,
Streptococcus pneumoniae and Haemophilus influenzae
[88] and between S. pneumoniae and H. influenzae [89]).
The same restriction applies for in vitro modelling of
host-microbe interactions in CRS as existing models are
co-culture systems of host cells with one or two micro-
bial species (e.g. airway epithelial cells with S. aureus)
[68, 90]. These models allow investigation of specific in-
flammatory mechanisms, competition between microbial
species and particular host-microbe exchanges. However,
they suffer from a reduced complexity, unable to mimic
the role of the commensal microbiota in this multifac-
torial disease. An overview of current in vitro models for
CRS is given.
Mimicking the host microenvironment
Interest in upper respiratory tract diseases has resulted
in the development of multiple in vitro models to study
the response of airway epithelium to allergen and anti-
gen exposure. Models that can be used to mimic upper
airway epithelium are two-dimensional monolayers (2D),
differentiated pseudostratified cell layers either sub-
merged or at air-liquid interface (ALI) (between 2D and
3D) and 3D cell culture models (co-cultures, explants
and 3D scaffolds). Microporous polymer membranes
and conventional plates are commonly used and can be
adjusted with coatings (2.5D culture), most often colla-
gen, to mimic the natural extracellular matrix [91]. Al-
ternatively, biomimetic (electrospun) structures [87, 92]
or decellularized tissues [93] can be used as substrates
for cell culture. The choice of substrate is important as
it can influence cell attachment, polarity, differentiation
and barrier formation [91].
Cell types Immortal cell lines commonly used to mimic
the URT are 16HBE (human bronchial epithelial cells)
and Calu-3 and A549 (cells from human lung carcin-
oma) [94–96]. Immortal cell lines have the advantages of
easy acquisition, source reliability and low cost. The abil-
ity to repeat experiments and yield reproducible results
is another benefit. Disadvantages of immortal cell lines
are the altered geno- and phenotype compared to in vivo
tissue and the inability to obtain a desired disease
phenotype (e.g. CRS). Furthermore, tissue-specific
material is not always available or adequate for use in
particular experiments. Primary patient material, such as
cells from nasal brushings and epithelial cells isolated
from sinus tissue or nasal polyps, has the advantage of
retaining an in vivo-like phenotype and can be both dis-
ease- and tissue-specific [54, 62, 68]. Disease-specific
materials, such as nasal polyp-derived cells, model the
impaired sinonasal epithelium more accurately in terms
of paracellular permeability and ciliary movement [54].
Disadvantages of primary patient material are the source
variability, the ethical issues with sampling, the high
cost, the low reproducibility due to biological variation
and the specialised laboratory personnel required. How-
ever, there has been an increase in the commercial avail-
ability of primary cells and disease-specific primary cells
(e.g. American Type Culture Collection®), partly
overcoming these drawbacks.
Conventional monolayers or suspension cultures 2D
monolayers in conventional plastic plates and membrane
inserts are the most commonly used models for airway
epithelial cell cultures. They can be optimised with coat-
ings (e.g. collagen), sometimes referred to as 2.5D cell
culture [91]. They are easy in use and are relatively low
in labour intensity, requirement for specialised labora-
tory personnel, time demand and cost. Airway epithelial
cell monolayers are obtained by seeding cells on a sub-
strate or scaffold and culturing them until fully conflu-
ent. 2D monolayers of, for example, but not limited to,
primary human nasal epithelial cells can be repeatedly
brought to ALI to study exposure to specified atmos-
pheric conditions. During ALI conditions, cells cultured
on porous (membrane) inserts are deprived of medium
in the apical compartment, exposing them to the atmos-
phere and requiring them to take up nutrients from the
basolateral compartment. These conditions allow the cell
layer to mimic in vivo functionality more closely than
immortal cell lines in submerged culture [97]. Despite
the obvious advantages offered by this model, it should
be noted that 2D monolayers differ significantly from in
vivo epithelial structures and differentiated ALI cultures.
In a study by Clark et al. [98], the transcriptional profiles
of a 2D monolayer and a differentiated ALI structure,
both consisting of primary human tracheal epithelial
cells, were compared in an unstimulated state and fol-
lowing stimulation with flagellin. Flagellin is the main
component of flagella and is primarily recognised by and
activates downstream signalling of Toll-like receptor 5.
The most important source of variation between the
transcriptional profiles appeared to be the culture
method (2D monolayer versus ALI culture), as opposed
to flagellin stimulation. 2D monolayers displayed a more
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extensive immune response upon flagellin exposure
compared to ALI cultures. The monolayer-stimulated
transcriptional profile was characterised by upregulation
of a wide array of genes involved in wound repair, in-
flammation and immunity, whereas a more modest re-
sponse was observed in ALI cultures. This muted
response might represent a more in vivo-like behaviour
and serve as a protection against an excessive pro-
inflammatory reaction. Research on the host response
upon stimulation with bacterial material or allergens is
not limited to epithelial structures but can be expanded
into the immune compartment. Suspension cultures of
immune cells can be used to examine immunological
responses to CRS-associated allergens. Larsen et al. [99]
used UV-killed commensal and pathogenic airway bac-
teria to examine dendritic cell maturation and pro- and
anti-inflammatory immune stimulation to shed light on
the role of changes in the airway microbiota in inflam-
matory airway diseases. Li et al. [100] used this method
to study the reaction of peripheral blood monocytic
cells to heat-killed S. aureus and observed downregula-
tion of TH1 responses, offering a possible explanation
for the TH2 inflammatory environment often observed
in CRS.
Between 2D and 3D: differentiated cell layers A well-
established model for airway epithelium research is cell
culture with differentiated airway epithelium at ALI. In
practice, airway epithelial cells (cell lines or primary
cells) are seeded on a microporous membrane and kept
under submerged conditions, with medium in both ap-
ical and basal compartments, until full confluence (2D
conventional monolayer). When the monolayer has
reached confluency, the medium on the apical side is re-
moved. This leaves the apical side exposed to air, while
nutrients and fluids need to be obtained from the basal
compartment. Apical exposure to air results in more
representative mucus production compared to sub-
mersed culture in an airway epithelial cell line (Calu-3)
[96]. At this point, the monolayer can differentiate in a
period of 2–4 weeks from a 2D conventional monolayer
to a polarised, pseudostratified epithelial structure com-
posed of basal cells, ciliated cells and mucin-secreting
goblet cells [62]. Differentiated cell layers are the follow-
up stage of 2D monolayers but can be distinguished
from the latter by their morphology and functionality.
The multi-layered epithelial structure mimics the
physiological barrier function in the respiratory tract
with its functional tight junctions. ALI cultures have a
more representative phenotype of the in vivo epithelium
and can be maintained for a longer period (weeks to
months) in comparison with medium-submerged mono-
layers [95, 101, 102]. A fully automated model for ALI
culture of primary cells, called CULTEX® LTC-C (long-
term cultivation continuous) has been developed by Auf-
derheide et al. [103]. The CULTEX® LTC-C provides
temperature control, semi-continuous medium supply
and automated medium-level adjustment, hereby in-
creasing the quality and reproducibility of the culturing
process, while reducing the labour intensity of conven-
tional cell culture. Other non-automated differentiated
ALI models of the upper respiratory tract are commer-
cially available. The MucilAir™-HF model consists of pri-
mary nasal cells co-cultured with human fibroblasts, and
the EpiAirway™ model contains primary human tracheal/
bronchial cells and also exists as a co-culture with fibro-
blasts. Blume et al. [94] developed a dynamic microflui-
dic model of differentiated primary airway epithelial cells
at ALI that allows close monitoring of immune re-
sponses of the cell layer. These different airway epithelial
models allow research on exposure to environmental al-
lergens [94, 104–106] and could be optimised for dis-
ease-specific purposes. Epithelial response to the
presence of bacteria can be simulated by exposure to
bacterial cell wall components such as lipopolysac-
charide (LPS), flagellin or bacterial toxins such as S.
aureus enterotoxin B and S. aureus alpha toxin, upon
which innate immune responses of CRS-derived cul-
tures can be compared to those originating from
healthy controls [54, 69, 98].
Multicellular models and 3D scaffolds The combin-
ation of different cell types within a model is a strategy
to more accurately represent the host microenvironment
and the interactions therein. Benam et al. [107] devel-
oped an ALI lung-on-chip model of human bronchioles
with epithelial and endothelial tissue to investigate in-
flammatory reactions in chronic obstructive pulmonary
disease and asthma. This model comprised an endothe-
lial cell layer with primary cells to mimic the expression
of receptors required for neutrophil rolling (transient ad-
hesion to E-selectin) and more firm adhesion (to ICAM-
1), as observed during in vivo inflammation. Recently,
an immunocompetent 3D model at ALI of the upper re-
spiratory tract was developed [87]. The tri-culture model
consisted of three biomimetic electrospun scaffolds upon
which, from bottom to top, respectively fibroblasts
(MRC-5 cell line), dendritic cells (isolated from per-
ipheral blood lymphocytes) and differentiated epithe-
lial cells (Calu-3 cell line) were grown. As a proof of
concept of immune response, dendritic cells were
shown to migrate through the scaffolds and cell layers
upon allergen exposure.
Host-microbe co-culture models
Host-microbe co-culture models offer the possibility to
investigate host-microbe interaction in a controlled en-
vironment with reduced complexity compared to human
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and animal models. This facilitates control of specific
conditions and exploration of novel therapeutic strat-
egies. The improved technical ability to create in vitro
differentiated host models and the combination with
multiple omics techniques allows improved insight in
host-microbe crosstalk during infection and (inflamma-
tory) responses [35, 68, 108]. Current co-culture models
of the respiratory tract have mainly focused on colonisa-
tion with a single pathogenic [68, 90, 108, 109] or pro-
biotic species [110]. The models can be used to monitor
short-term host-microbe interactions, such as innate im-
mune responses of the epithelial cells and physiological
changes of bacterial and epithelial cells such as cytokine
production and tight junction functionality [68, 90].
Starner et al. [109] developed the first in vitro model for
bacterial biofilm formation on polarised human airway
epithelia. Differentiated Calu-3 epithelial cells at ALI
were used in co-culture with H. influenzae for four con-
secutive days, during which the epithelial cells remained
viable. The model allowed follow-up of innate immune
responses and biofilm formation. A similar set-up was
used to study S. aureus colonisation of airway epithelial
cells and the physiological changes that occurred during
the colonisation process [90]. However, the epithelial
layer was completely disrupted within 1 day after inocu-
lation of wild-type S. aureus. Baddal et al. [108] have
used simultaneous whole genome transcriptional
profiling of host cells and a H. influenzae strain invading
primary differentiated airway epithelium. Pathogen-
mediated signalling pathways and significant dysregula-
tion of the target cytoskeletal network upon intracellular
infection were identified. This approach also enabled
discovery of host adaptation pathways in the pathogen
and metabolic signature traits of nasopharyngeal colonisa-
tion. Another co-culture model to study early innate im-
mune responses of airway epithelium upon bacterial
infection was developed by Kohanski and Lane [68]. The
host environment was mimicked by an ALI-differentiated
structure of sinonasal epithelial cells from CRS patients
with and without nasal polyps and non-CRS controls. Dis-
tinguished inflammatory responses could be observed for
the CRS subtypes upon infection with S. aureus, suggest-
ing that the primary material has an inflammatory mem-
ory and could therefore be used to mimic the host
environment more adequately. A submerged monolayer
of human bronchial epithelium cells (HBE014 cell line)
was used to investigate phenotype switching to small col-
ony variants of S. aureus upon internalisation in epithelial
cells and the subsequent effect on the immune response
[111]. It was shown that intracellular S. aureus did not
elicit excretion of the pro-inflammatory IL-6, contrarily to
extracellular S. aureus. Cytotoxic effects were neither in-
duced. A similar approach was followed to examine the
differences between wild type and small colony producing
S. aureus in epithelial cell invasion and subsequent host
immune response [112]. Small colony variant producing S.
aureus was shown to elicit a less widespread innate im-
mune response at similar colonisation rates, thus evading
clearance by the host. These findings could help explain
bacterial persistence in CRS [111, 112].
Existing models are limited in the time frame of the
host-microbe co-culture and the ability to adequately
mimic the URT microenvironment; due to cell toxicity,
the duration of host-live microbe co-cultures with direct
contact between mammalian cells and bacteria is
currently limited to hours or days [68, 90, 108]. This
duration can be used for investigation of initial attach-
ment and colonisation of bacteria but does not permit
examination of bacterial persistence strategies. Starner et
al. [109] inoculated H. influenzae with a multiplicity of
infection of 20 bacteria/host cell and retained viable epi-
thelial cells until 4 days post-inoculation. Remarkably,
Ren et al. [113, 114] have used the EpiAirway™ model for
co-culture of the host compartment with H. influenzae,
extending the co-culture period to 10 days. Key aspects
for success were the low multiplicity of infection (0.01–
10 bacteria/host cell) and daily washes with phosphate-
buffered saline. Another limitation to current models is
failure of the host compartment to adequately mimic the
host microenvironment as most often undifferentiated
host cell monolayers or differentiated epithelial cell
cultures are used, without taking into account tissue-
specific mechanical or chemical stimuli. Organ-on-chip
models offer a way to take these stimuli into account
mimicking the spatial structures and mechanical stimuli
observed in host tissue in microfluidic devices [107, 115,
116]. The ALI culture method, also applied in these de-
vices, provides conditions for co-culture resembling the
in vivo situation, where bacteria are exposed to atmos-
pheric conditions and are obliged to acquire nutrients
and growth factors through the epithelial cell layer.
Microbial co-culture models
The majority of in vitro studies on URT infections have
focused on competition assays between two microbial
species. However, model systems for the URT micro-
biota in health and CRS are required to gain mechanistic
insight in the factors that influence microbial colonisa-
tion behaviour, growth characteristics and community
composition and the impact thereof on the expression of
pathogenic traits and disease aetiology and evolution.
Mucostasis, a result of reduced ciliary movement and ost-
ium obstruction, is commonly observed in the paranasal si-
nuses of CRS patients and can result in the accumulation
of microorganisms and other immunogenic compounds in
the paranasal sinuses. Furthermore, it alters the spatial
structure of the growth surface of the bacterial community,
a parameter known to impact colonisation behaviour [117].
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The altered, inflammatory microenvironment can influence
the community composition, as some species are more
susceptible to host defence mechanisms than others.
Microbial co-culture models can range from two-species
co-cultivation over synthetic communities to natural com-
munities. Simple co-cultivation models offer the advan-
tage of a low complexity, high controllability and relative
ease to analyse, but often lack representative in vivo be-
haviour. Natural communities typically display a higher
level of complexity and have a broader and more repre-
sentative functionality. Disadvantages are the lower con-
trollability and reproducibility and difficulty of analysis.
Synthetic communities combine the advantages of both
systems by having a broader functionality than simple co-
cultures, while being more controllable and reproducible
than complex communities [118]. Recent research on
healthy and CRS sinonasal microbiota indicates the exist-
ence of community state types [119] or disease subgroups
[9] with distinctive bacterial compositions. This offers the
opportunity to develop different synthetic communities
associated with CRS phenotypes and opens the way to
precision research and medicine.
Competition assays between two microbial species en-
able the investigation of specific interaction between
these species in a relatively simple set-up and may lead
to discovery of novel strategies to prevent pathogenic in-
fections. Biofilm co-culture experiments are especially
relevant in CRS research and have for example been
used to study species interactions before and during the
biofilm state. In vitro studies demonstrated that
Staphylococcus epidermidis can have an inhibitory effect
on S. aureus biofilm formation [120, 121], partly explain-
ing the negative correlation between S. epidermidis col-
onisation and S. aureus carriage observed in hospitalised
patients [122]. S. aureus and H. influenzae are regularly
observed together in CRS-associated biofilms [85]. The
interactions between S. pneumoniae and H. influenzae
were investigated during pre-biofilm planktonic growth
and biofilm formation, and the inclination towards an-
tagonism or mutualism was shown to be largely
dependent on environmental parameters such as growth
phase and nutrient availability [123]. Interspecies inter-
actions in S. aureus biofilm formation and co-
aggregation were examined between nostril-dwelling S.
aureus and Propionibacterium spp., where a porphyrin
compound excreted by Propionibacterium spp. was
found to induce S. aureus aggregation and biofilm for-
mation [124]. More simplistic co-culture models include
agar competition experiments and broth co-culture.
Cope et al. [89] demonstrated interspecies interactions
and their influence on virulence gene expression be-
tween H. influenzae and S. pneumoniae both in vitro
and ex vivo in human CRS sinus tissue. H. influenzae
type IV pili, important for epithelial colonisation and
biofilm formation, were only expressed in co-culture in
vitro, whereas S. pneumoniae virulence factors associ-
ated with acute infection and epithelial damage were
downregulated, adhering to a more chronic infection
model. Yan et al. [25] first studied bacterial community
differences between persistent and non-persistent S. aur-
eus carriers and found a co-occurrence between S. aureus
and Corynebacterium accolens, while Corynebacterium
pseudodiphteriticum was observed more often in non-
persistent carriers. Growth interaction assays on agar
plates revealed that S. aureus and C. accolens supported
each others’ growth, while C. pseudodiphteriticum growth
was less supported by S. aureus and C. pseudodiphteriti-
cum even inhibited S. aureus [25].
CRS is a multifactorial disease, as elaborated previ-
ously, and despite the established importance of S. aur-
eus and other pathogenic species in the disease, it is
unlikely to be caused by a single infectious microorgan-
ism. It is rather to be expected that, on the bacterial side,
an imbalance in the microbial community plays a role.
The reductionist approach of two or multiple species co-
cultures is unable to answer research questions on col-
onisation and growth dynamics in the complex, pre-
colonised mucosal environment seen in CRS. Consider-
ing CRS as a poly-microbial disease, research on com-
plex communities, deciphering co-occurrence patterns,
mutualistic interactions and the importance of the rela-
tive abundance of the community members, is indis-
pensable to understand CRS and find appropriate
treatment or preventive strategies [125]. Reduced com-
munity evenness has been shown to decrease resistance
to invasion [126], which could facilitate pathogen colon-
isation in CRS community in state of dysbiosis and fur-
ther CRS pathogenesis. It is in this ecosystemic
framework that further CRS research initiatives should
take place.
Bacterial co- or mixed culture experiments have the
major disadvantage of omitting the host’s immune re-
sponses and thus omitting within-host competition be-
haviour [127] and more broadly the effects of microbial
co-infection [128, 129]. Within-host competition is a
strategy during which a species elicits an immune re-
sponse to which it is resistant itself, but that is able to
clear the niche of competing organisms. These off-target
immune defences comprise cross-reacting antibodies, re-
cruitment of polymorphonuclear cells and production of
antimicrobial proteins. Immunological effects can se-
verely influence and even revert competition outcomes
compared to in vitro observations [127].
Conclusion
Chronic rhinosinusitis is a multifactorial disease of uncer-
tain aetiology, driven by host immune responses, micro-
bial dysbiosis and exposure to environmental irritants.
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Mechanistic research to unravel aetiopathologic pathways
of this disease and find innovative prophylactic or treat-
ment approaches requires in vitro models of the affected
tissues and their resident microbiota. Current models are
either limited to host cells, competition assays between
few airway species or simple host-pathogen co-cultures.
To adequately mimic host and microbial behaviour in
CRS, a less reductionist approach is needed, in particular
on the microbial aspect. A polymicrobial, dynamic com-
munity is a prerequisite to investigate pathogen colonisa-
tion and inflammatory responses elicited in the host.
Long-term models are needed to analyse shifts in the mi-
crobial community composition and functionality during
CRS and how these communities can be modulated to im-
prove chronic inflammation and restore host-microbe bal-
ance in the sinonasal cavities.
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